Hasil Pencarian - M. Jalving

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response

    Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response oleh J.S. Hooiveld-Noeken, R.S.N. Fehrmann, E.G.E. de Vries, M. Jalving

    Diterbitkan 2019-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Independent Induction of Caspase-8 and cFLIP Expression during Colorectal Carcinogenesis in Sporadic and HNPCC Adenomas and Carcinomas

    Independent Induction of Caspase-8 and cFLIP Expression during Colorectal Carcinogenesis in Sporadic and HNPCC Adenomas and Carcinomas oleh D. M. Heijink, J. H. Kleibeuker, M. Jalving, W. Boersma-van Ekb, J. J. Koornstra, J. Wesseling, S. de Jong

    Diterbitkan 2007-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines

    Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines oleh V. C. Leeuwenburgh, C. G. Urzúa-Traslaviña, A. Bhattacharya, M. T. C. Walvoort, M. Jalving, S. de Jong, R. S. N. Fehrmann

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

    Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer oleh E. C. de Heer, C. E. Zois, E. Bridges, B. van der Vegt, H. Sheldon, W. A. Veldman, M. C. Zwager, T. van der Sluis, S. Haider, T. Morita, O. Baba, C. P. Schröder, S. de Jong, A. L. Harris, M. Jalving

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

    Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer oleh E. C. de Heer, C. E. Zois, E. Bridges, B. van der Vegt, H. Sheldon, W. A. Veldman, M. C. Zwager, T. van der Sluis, S. Haider, T. Morita, O. Baba, C. P. Schröder, S. de Jong, A. L. Harris, M. Jalving

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients

    Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients oleh S. T. Paijens, A. Vledder, D. Loiero, E. W. Duiker, J. Bart, A. M. Hendriks, M. Jalving, H. H. Workel, H. Hollema, N. Werner, A. Plat, G. B. A. Wisman, R. Yigit, H. Arts, A. J. Kruse, N.M. de Lange, V. H. Koelzer, M. de Bruyn, H. W. Nijman

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

    Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated wi... oleh J. C. Janssen, B. van Dijk, K. de Joode, M. J. B. Aarts, F. W. P. J. van den Berkmortel, C. U. Blank, M. J. Boers-Sonderen, A. J. M. van den Eertwegh, J. W. B. de Groot, M. Jalving, M. J. A. de Jonge, A. Joosse, E. Kapiteijn, A. M. Kamphuis-Huismans, K. A. T. Naipal, D. Piersma, B. Rikhof, H. M. Westgeest, G. Vreugdenhil, E. Oomen-de Hoop, E. E. A. P. Mulder, Astrid A. M. van der Veldt

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: